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ABSTRACT 
Women carrying mutations in either BRCA 1 or BRCA2 have a lifetime risk of breast cancer of 
80%.  As little is known about the risk of other malignancies, apart from ovarian/tubal cancer in 
mutation carriers, the importance of other malignancies in a family with several cases of breast 
cancer is hard to evaluate.  Women at high risk of breast cancer due to family history are 
offered genetic counselling and surveillance. Whether women looking for oncogenetic 
counselling are, in terms of socioeconomic status and health-related quality of life, comparable 
with women in general is not known. Mammography is a widely used screening method to 
detect breast cancer and has proven to reduce breast cancer mortality in women older than 50 
years. The sensitivity of the method is much lower in women with dense breast and in general 
young women tend to have denser breast than older women. Most women under surveillance in 
virtue of family history of breast cancer are younger than 50, thus in a group where 
mammography alone has not been proved to be effective as a single screening method there is a 
need for other surveillance methods in women at risk of hereditary breast cancer. 
 
We identified 803 BRCA 1/2-negative families with two or more cases of breast cancer and at 
least one additional malignancy. The observed proportion of different non-breast cancer in the 
study families was compared with the percentage distribution of non-breast cancer tumours in 
Sweden. Tumours in endometrium were seen in a significantly larger proportion in the study 
group than in the general population and could not be explained by previously known 
syndromes or other explanations for being overrepresented. Thus we suggest that endometrial 
carcinoma and breast cancer constitute a new breast cancer syndrome. 
 
In a cross-sectional study aiming to characterize health-related quality of life and 
socioeconomic status among all healthy women who had ever visited the Oncogenetic Clinic, 
Department of Oncology, Södersjukhuset in 1998 – 2004, 306 women consented to participate 
(82.5%). Significantly more women in the study group were cohabiting (74.2 vs. 43.8%), had 
the highest education level, (56.7 vs. 39.6%) and had the highest household income (36.9 vs. 
12.9 %) as compared to the reference population in the same catchment area. Study subjects 
reported significantly lower levels of health-related quality of life for subscales related to 
mental health and for general health compared to normative data, but similar levels on 
subscales related to physical health.    
                                                                                                                                                        
Six-hundred-and-thirty-two women (94%) from one counselling clinic consented to participate 
in a study aiming to find the most sensitive method to detect breast cancer in women with a 
familiar risk of the disease. Every woman underwent yearly, and blinded to the other methods, 
mammography, ultrasound and clinical breast exam. This first report describes the study design 
and the procedure, and the study cohort regarding hereditary pattern and sociodemographics. 
Further, the associations between breast density, BMI and other breast-cancer risk factors are 
elucidated. High breast density was associated with low BMI and young age. However, high 
density was not associated with increasing risk of breast cancer. Ultrasound and clinical breast 
examination caused substantially more work-up than MG. The number of detected cancers did 
not differ from the expected numbers. However, it is too early to draw any conclusion about the 
sensitivity of the three different modalities..  
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1 GENERAL INTRODUCTION 
Nearly 12.7 million new cancer cases and 7.6 million cancer deaths occurred in 2008 
worldwide, and breast cancer is by far the most frequent cancer among women. In 2008  
almost 1.4 million females were afflicted with the disease which constitutes almost a 
quarter of all cancers in women. Despite a wide range of incidence in different regions, 
with the highest rates in western countries, breast cancer is the most common form in 
females both in developed and in developing countries. (GLOBOCAN, 2008) 
 
Fig 1  Incidence and mortality in different regions (GLOBOCAN, 2008). Estimated ASR 
(world) per 100 000 
In Sweden like in many developed countries approximately  every tenth to eighth 
woman will be afflicted by breast cancer at some time, and 7380 women were 
diagnosed with the disease in 2009 (Swedish Cancer Registry, 2009). Most cases occur 
late in life and are sporadic. A Scandinavian twin study has revealed that hereditary 
factors are of importance in 27% of all breast cancers  (Lichtenstein P, 2000), and 5-
10% of cases appear to be the result of autosomal dominant genes (Claus EB , 1991). 
Familial aggregations of breast cancer have been observed all over the world; in 
general, early onset and bilateral disease are two important features in these families  
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(Claus EB, 1990) thus making  heredity, together with gender, age and extensive dense 
breast tissue on mammogram, the most important risk factor for the disease.  
        
So far BRCA1 and BRCA2 are the only two genes available on a daily clinical basis to 
be screened in families with clustered breast and /or ovarian cancer. In most families 
with a pattern of hereditary breast cancer, no mutation can be found and in these 
families, only a risk of breast cancer is considered. As little is known about the risk of 
other malignancies, apart from ovarian/tubal cancer in mutation carriers, the importance 
of other malignancies in a family with several cases of breast cancer is hard to evaluate. 
   
No published data suggests that family clustering of breast cancer of genetic origin is 
more prevalent in one socioeconomic group than in another. Consequently the need for 
oncogenetic counselling ought to be evenly distributed in a population. Many studies 
have revealed low socioeconomic status as a risk factor for non-attendance at health 
care such as population-screening mammography  (Lagerlund M, 2002)(Katz SJ, 
2000). Descriptive reports of women attending breast-cancer risk-assessment 
programmes show that these women tend to be well-educated and of middle or upper 
income status (Bastani R, 1999) (Watson M, 2005).  Numerous studies have explored 
psychological factors in women attending oncogenetic counselling and in general they 
report worse scores for anxiety, distress and depression than for women in the general 
population (Cull A) (Martin W, 2006) (van Dooren S, 2004).    
Mammography has long been the basic screening modality for breast cancer 
surveillance. However, sensitivity is less in women with dense breast and in general 
young women tend to have denser breasts (Wolfe, 1976)  (El-Bastawissi AY, 2000). 
Also, women attending surveillance programmes tend to be young. At the same time, 
the relative risk of breast cancer in women with very high breast density is substantially 
higher than in those with lucent breasts (Chiu SY, 2010)  (Heusinger K, 2011)(Wolfe, 
1976).Ultrasound of the breast has for several years been used to supplement 
mammography but is not established for screening on its own. Though widely used and 
recommended, clinical breast exam has not yet been evaluated as a tool for the 
surveillance of women at high risk for the disease.  
 
This work reported in this thesis concerned finding women who will benefit the most 
from oncogenetic counselling and surveillance, and finding the best way of 
surveillance.  
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1.1  RISK FACTORS FOR BREAST CANCER 
1.1.1 Hormonal factors 
Reproductive factors such as early menarche, late menopause, null parity, high age at 
first partum, no breast feeding all contribute to a longer or more intense fertile period, 
which is believed to heighten the risk of breast cancer (Veronesi U 2005) (Kelsey JL 
1993). Though accounted hormonal risk factors, some of these factors certainly also 
have genetic/inherited backgrounds. 
Other hormonal factors. Current use of hormonal replacement therapy (HRT) is 
nowadays an established risk factor for breast cancer if used for three or more years. 
Oral contraceptives also contribute to the risk, but the figures here are not as evident as 
for HRT.  (Veronesi U 2005) 
Table 1 Selections of risk factors in breast cancer and corresponding relative risks for 
women.  Adapted from Veronesi, 2005 
Age Relative Risk (RR) High-risk group 
Age >10 Elderly individuals 
Geographical location 5 Developed countries 
Breast density >5 Extensive dense breast tissue 
visible on mammogram 
Age at menarche 3 Before age 11 years 
Age at menopause 2 After age 54 years 
Age at first full pregnancy 3 First child after age 40 years 
Family history ≥2 Breast cancer in first-degree 
relative 
Prev benign breast disease 4–5 Atypical hyperplasia 
Cancer in other breast >4 Previous breast cancer 
Socioeconomic group 2 Groups I and II* 
Body-mass index   
Premenopause 0·7 High body-mass index 
Postmenopause 2 High body-mass index 
Alcohol consumption 1·07 7% increase with every daily 
drink 
Exp. to ionisation radiation 3 Abnormal exposure to young 
girls after age 10 years 
Breastfeeding and parity   
Relative risk falls by 4·3% for 
every 12 months of 
breastfeeding in addition to a 
7% reduction for every birth,  
 Women who do not 
breastfeed, 
Use of exogenous hormone   
Oral contraceptives 1·2 Current users 
HRT 1·66 Current users 
Diethylstilbestrol 2 Use during pregnancy 
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Anthropometric factors.  
Having a low BMI at the age of 18 as well as having a BMI over 25 postmenopausally 
both raise the risk of breast cancer. The relative risk per height increment of 5 cm has 
been estimated to 1.02 (95% CI 0.96-1.10) in premenopausal women and 1.07(1.03-
1.12) in postmenopausal women (Veronesi U 2005). 
   
1.1.2  Demographic factors 
Demographic factors include age, gender and geographic area. Breast cancer incidence 
in Sweden peaks at the age of 63 years (Swedish Cancer Registry, 2009).Breast cancer 
in men constitutes 0.5% of all cases. Breast cancer in western countries such as the 
USA, Scandinavia and the UK will occur in approximately every eighth to tenth 
woman. In Mediterranean countries e.g. Spain, the incidence is less than half that in the 
former countries while in China and Japan the corresponding lifetime figure is 2% 
(GLOBOCAN 2008).     
 
1.1.3  Breast properties.  
Breast with a dense mammographic pattern is associated with a relative breast-cancer 
risk of up to 6 times (N. F. Boyd 1995). A previous biopsy showing a pattern of lobular 
cancer in situ (LCIS) from either breast gives a risk of 20% of malign tumour in either 
breast. However, LCIS is looked upon as a marker of increased risk rather than an 
anatomic precursor of malignancy (Nelia Afonso 2008). Atypical ductal hyperplasia 
(ADH) constitutes an overall risk of 2.4 of getting a malign tumour later (L M Marshall 
1997).  
 
1.1.4 Daily intake of alcohol.  
Many studies postulate alcohol as positively associated with breast cancer in 
postmenopausal women, already elevated with moderate consumption (>10 g/day)  
(Lew JQ, 2009). Lew et al also conclude that associations are stronger with hormone-
positive tumours than with hormone negative ones. They also found an association with 
long-term use of HRT. In a multicentre prospective study in ten European countries 
(Lois B. Travis, 2005) of over 250, 000 women, 5% of all incident cases of breast 
cancer (n=12 589) were attributed to alcohol (Schütze M 2011).  
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1.1.5 Regular physical exercise 
Regular physical exercise is believed to reduce the risk of breast cancer. Numerous 
studies provide evidence of this in postmenopausal women (Awatef M 2011). In a 
review of 62 studies Friedenreich et al 2008 found in the majority of these studies an 
average risk decrease of 25-30% among the most physically active women compared 
with the least physically active (Friedenreich CM 2010). In  contrast,  Awatef et al, like 
in many other studies (Magnusson CM 2005), found no corresponding risk reduction 
among premenopausal women.                                                                                                                   
 
1.1.6 Previous ionization radiation 
Previous ionization radiation of the breast region. Numerous studies reveal an increased 
risk of breast cancer in long-term survivors of Hodgkin’s disease after radiotherapy  
(Travis LB, 2005). A comparison between long-term survivors treated at a high 
radiation dose delivered to the breast showed an association with an eightfold increased 
risk compared with that in patients who received lower doses (Travis LB, 2005). 
 
1.1.7 Genetic risk factors 
Close relatives with breast cancer.  
As a rule of thumb, the risk gets higher with every case of breast cancer in the close 
family as well as with an earlier onset for each case.  
 
Autosomal-dominant inherited mutations in certain genes are associated with an 
increased risk of breast cancer. Breast cancer in association with other tumours 
constitutes different syndromes in these families. 
 
1.1.7.1 BRCA 1 and BRCA2. 
 In 1994 and 1995 respectively the two tumour-suppressor genes BRCA 1  (Miki Y, 
1994) and  BRCA 2 (Tavtigian SV, 1996) were cloned. In spite of enormous efforts in 
numerous scientific laboratories all over the world, so far BRCA 1 / 2 are the only two 
genes that could be offered on a daily clinical basis to be screened in families with 
clustered breast and /or ovarian cancer. Carrying a mutation in either gene involves a 
substantially elevated risk of breast cancer and ovarian/tubal cancer (Easton, 1995) 
(King, 2003). Carrying a mutation in either of these suppressor genes entails a 50- 80% 
lifetime risk of female breast cancer. Being a BRCA1 carrier confers a 30-60% risk of 
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ovarian/tubal cancer, whereas a carrier of mutation in BRCA2 has a 10-20 % life-time 
risk off the disease.  
 
 Although rare, other inherited syndromes associated with an increased risk of breast 
cancer and other tumours are known:  
 
1.1.7.2 Tumour protein 53 tumour gene TP53 
One example is the Li-Fraumeni syndrome, characterised by breast cancer occurring at 
an exceptionally young age in combination with brain tumour, adrenocortical 
carcinoma and soft-tissue sarcoma  (Li FP, 1969). This syndrome has also been 
associated with an overrepresentation of tumours in the stomach, colon, rectum, 
pancreas, and ovary as well as malignant lymphoma, all at an extremely young age and 
along with the typical tumours constituting a classical Li-Fraumeni syndrome (Nichols 
KE, 2001). Earlier studies have found mutations in the causative gene TP53, rarely seen 
in families where breast cancer cases predominate (Zelada-Hedman M, 1997). In 
contrast, a study by Mouchawar published in 2010 demonstrated a 5% risk of TP53 
mutation in women  affected with breast cancer at an age under 35 years if they had one 
or several close relative (CR) with breast cancer. In women below 35 of age and with 
no family history of breast cancer a 3% risk was demonstrated (Mouchawar J, 2010). 
This will probably lead to a change in counselling so that that women with breast 
cancer under the age of 35 tested negative for mutations in BRCA 1 and BRCA 2 will 
be offered mutation analysis in TP53. In other respects, carriers of TP53 mutations are 
also at substantial risk of malignancies of many other origins and also a substantial risk 
of malignant tumours during childhood and adolescence. Screening methods for 
malignancies in other organs than breasts have not been established or evaluated in this 
context. For this reason, counselling is complicated and the advantage of finding a 
mutation in TP53 in a family is not always obvious. 
 
1.1.7.3 Phosphatase and tensin homologue  PTEN.  
In Cowden’s syndrome, females are afflicted with malignant tumours of the breast and 
the thyroid gland caused by germ line mutations in the suppressor gene PTEN (Liaw D, 
1997). PTEN mutations in familial breast cancer outside this syndrome are rare (Chen 
J, 1998) (Guénard F 2007). 
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1.1.7.4 Ataxia-telangiectasia (mutated gene) ATM.  
The role of ataxia-telangiectasia mutated gene heterozygosity in breast cancer has been 
controversial. Heterozygotes represent increased risk, in particular at older age (Athma 
P, 1996). Occasional germ line mutations have also been reported in familial breast 
cancer(Chen J B. G., 1998).  
 
1.1.7.5 E-Cadherin.  
Germ line mutations in the tumour suppressor gene E-Cadherin are associated with an 
increased risk of diffuse gastric cancer and to some extent also of lobular breast 
carcinoma, but are not seen (Keller G, 1999) (Salahshor S, 2001)or very rarely 
(Schrader KA, 2011) in familial breast cancer without diffuse gastric cancer.     
 
1.1.7.6 Chek point kinase2, CHEK2 
Some families with the Li-Fraumeni phenotype also bear mutations in the CHEK2 gene 
(Bell DW, 1999). Studies of families with multiple cases of breast cancer indicate that a 
certain mutation in the CHEK2 gene, 1100delC, is associated with an increased risk of 
both sporadic and familial breast cancer (CHEK2 breast cancer case-control 
consortium,2004). In a recent study from Finland, 82 well- characterized, high-risk 
hereditary breast and/or ovarian cancer  BRCA1/2-founder negative individuals were 
screened for germ line mutations in seven breast-cancer-susceptibility genes including 
CHEK2.  Fairly many mutations, 12.2%, were found in CHEK2 among theses women, 
but the finding warrants further segregation analyses to evaluate the clinical 
significance (Kuusisto KM, 2011). 
 
1.1.7.7 Cyclin-dependent kinase inhibitor 2A CDKN2A 
An increased familial risk of breast cancer and pancreatic cancer has been described in 
Swedish families segregating the cyclin-dependent kinase inhibitor 2A, CDKN2A/p16-
mutation and showing multiple cases of malignant melanoma  (Borg A 2000).  
 
Other genes such as BRIP, PLAB2 and RAD 51C are even more rarely seen in 
populations of hereditary-breast-cancer families (Wong MW, 2011). 
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1.2 ONCOGENETIC COUNSELLING 
 
1.2.1 Procedure 
1.2.1.1 Awareness 
Awareness of family history of breast cancer as a risk factor is growing in the Swedish 
general population for several reasons. There is growing awareness of family history of 
breast cancer as a risk factor among nurses, physicians and others working in the health 
system. Family members in a counselled family, where an enhanced risk for the disease 
has been identified, are encouraged to spread information to other family members 
about the risk. The media have given attention to the issue in different ways, including 
focus on individual young women affected with hereditary breast cancer.  These factors 
certainly have led to more and more women at high risk of the disease being identified.  
 
1.2.1.2 Family composition   
Almost all individuals seeking information about breast cancer risk because one or 
several close relatives (CR) are affected with the disease, are females. In a study from 
Stockholm including 306 healthy women, we found that 50% had mothers affected 
with the disease. The second most common CRs with breast cancer were sisters. 
Substantially more CRs affected with breast malignancy were of maternal than of 
paternal origin. Concerning the individual composition of in these women's families, it 
was equally common for them to have one or more daughters as to have one or more 
sons and also just as many had sisters as they had brothers. The majority of these 
women, 57%, sought information about the risk of breast cancer in the family for their 
own sake in the first place and thereafter for the sake of their daughter/s. Of the306 
participating women five regretted undergoing counselling and in 14 cases there was a 
missing value. Thus, 287 women (96%) were pleased with counselling and would go 
through the procedure again had they known at the beginning what they knew 
afterwards. 
 
1.2.1.3 Getting to the counsellor 
First, someone must have been noticed in the family history of breast cancer in 
the family. It could be the woman herself, a relative or a friend who drew attention to 
the circumstance. It could also be someone in health care such as a gynaecologist or 
family doctor. Or it could be a nurse involved in mammography screening, who all are 
trained to ask invited women about their family history of breast cancer. The woman 
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could then be referred to the counselling clinic or could contact the clinic herself. At all 
counselling clinics in the Stockholm region the client will then be invited to contact the 
clinic for an appointment with the counsellor to start the procedure. 
 
 
1.2.1.4 Pedigree procedure 
At first appointment the counsellor will draw a pedigree including all first-, second- and 
third-degree family members on both sides that the proband, the person being 
counselled, is aware of. Year of birth and all known malignancies including age at 
onset are noted. The procedure to get the malignant diagnoses verified includes getting 
permission from the affected relative or, if deceased, from her/ his closest relative. 
Most of the diagnoses are histologically verified as shown by medical records or the 
Swedish Cancer Registry. A few cases originated from the beginning of the twentieth 
century, before the Registry was established. These are mostly verified by checking the 
Swedish Cause of Death Registry, to which doctors have been required to report all 
deaths since 1911. On average 80% of all tumours of breast and gynaecological origin 
in a family are verified (data from paper 3). Tumours of other origins that could be a 
part of BRCA 1or BRCA2 inheritance are also verified to a high degree, as are most 
other malignancies. 
 
1.2.2 Risk assessment 
1.2.2.1 Claus tables 
Claus tables (Claus EB, 1994) have been widely used. However they include only two 
close relatives for estimating lifetime risk of breast cancer.  
 
1.2.2.2 Autosomal-dominant inherited disease 
In families with three or more close relatives diagnosed with breast or ovarian cancer, it 
is assumed that there is an autosomal-dominant inherited disease. In families where 
mutations in any of the high-penetrance genes BRCA 1 or BRCA 2 have been ruled out 
or could not be tested for, a first-degree female relative of an affected women in such a 
family is thought to have a 50% chance of carrying a genetic aberration entailing 
increased risk of breast cancer. The penetrance for such a heritability is assumed to 
mimic the effect of mutations in BRCA 1 or 2;but there is great uncertainty in assessing 
the risk of breast cancer in these families.  
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1.2.2.3 Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation 
Algorithm [BOADICEA] 
Since 2009 the Breast and Ovarian Analysis of Disease Incidence and Carrier 
Estimation Algorithm [BOADICEA] risk estimation model has largely replaced Claus 
tables in the clinic at the Karolinska University Hospital in Stockholm. The 
BOADICEA is based on 1484 breast cancer cases and 156 multiple-case families 
mainly from England (AC Antoniou 2004). The model takes into account unlimited 
family members, family history of malignancies of breast (unilateral or bilateral) 
ovarian/tubal, pancreatic and prostate origin. Also taken into account are birth cohort, 
age at cancer onset, BRCA1/2 screening status and Jewish ancestry. A special web-
based risk assessment programme is available so that genetic counsellors can estimate 
the risk for every woman in a counselled family. The model also predicts the 
probability for a family member to be a carrier of a mutation in BRCA 1 and BRCA 2. 
However it is important to evaluate the accuracy of the model’s predictions in 
independent cohorts, which has not yet been done in data sets from a Swedish 
population.  
 
 
 
1.2.2.4 Testing for mutation according to The Swedish National Oncogenetic Group 
guidelines.  
In the counselling situation in Sweden, mutation analysis of the BRCA1 and BRCA2 
genes is usually offered to families fulfilling any of the following criteria;  
1) at least three cases of breast cancer in first-degree relatives, one of whom was under 
the age of 50 at the time of diagnosis,  
2) two first-degree relatives with breast cancer, one before the age of 40 years,  
3) one case of breast cancer before 35, 
4) any combination of breast cancer and ovarian cancer in a family regardless of age,  
5) one case of ovarian cancer before age 45.   
Among Swedish families with a pedigree fulfilling these criteria, fewer than one-third 
segregate mutations in either gene  (Einbeigi Z, 2001)  (Arver B C. A.-D., 1999). 
Families with a distribution of tumours typical for the Li-Fraumeni syndrome are 
offered mutation analyses of p53 but very few germ line p53 mutations have been 
found.  
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1.2.3 Surveillance 
Women with enhanced risk of breast cancer are recommended surveillance and 
proposed controls are mainly due to level of risk and of breast properties in these 
women. In Sweden the following recommendations are suggested to these women: 
Lifetime risk of breast cancer according to the BOADICEA model.  
 
• <17 %       
o No extra surveillance. Recommend population screening mammography 
and monthly breast self-examination (BSE). 
• 17-19 %    
o Population screening with mammography, but advance screening (annual 
mammography and ultrasound) from about five years before the 
youngest case in the family may be considered, if additional factors 
indicate increased risk.  
• >20 %      
o   Yearly diagnostic imaging from about five years before the youngest 
case in the family was afflicted. At follow-up before age 50 and where 
there are mammographically dense breasts, supplementary imaging such 
as ultrasound should be performed for increased sensitivity .  
• Mutation carriers BRCA 1 and BRCA2  
o Annual surveillance from 25 years of age, including visit to clinician and 
breast MRI.    
                       
Additionally all women are instructed in self-examinations and also encouraged to 
contact a cancer clinic if they observe any abnormalities in their breasts (my 
comments).  
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1.3 BREAST IMAGING METHODS 
1.3.1 Mammography  
The Swedish National Board of Health and Welfare advised on population-screening 
mammography as early as in 1986. This advice was based on early results from 
Swedish mammography trials and after gradual introduction the surveillance was 
introduced throughout the country eleven years later. Regular mammography screening 
followed by diagnosis and treatment leads to a significant reduction in breast cancer 
mortality, as stated by the EUSOMA (European Society of Mastology) in 1993. Meta-
analysis of six randomised controlled trials, including four Swedish ones, found 
statistically significant evidence for a 22% reduction in breast cancer mortality in 
women over 50 years of age. On the other hand, population-screening mammography 
in women under 50 has long been controversial and the efficacy of the method in this 
age-group has not been demonstrated consistently. Thus, some studies could not 
demonstrate any reduction in breast cancer mortality (Miller AB, 2002) while others 
reported non-significant reductions (Moss SM & Group, 2006), (Jonsson H, 2000). 
Hellquist et al have recently shown a significant reduction of relative risk (RR) of 
breast cancer mortality of 0.74 (95% CI, 0.66-0.83) among invited compared with not-
invited women aged 40-49 years (Hellquist BN, 2011). 
 
1.3.2 Ultrasound  
Ultrasound as a breast-imaging method is free from radiation and is a procedure that 
women in general find less uncomfortable than mammography.  The method is 
frequently used to supplement to MG and, unlike MG, can be used in pregnant women.  
Few studies have used US as a single screening modality with modern technique. Berg 
et al concluded, from a study of 2809 women with different types of elevated risk of 
breast cancer, that US yielded 1.1 to 7.2 extra cancers if added to MG but the method 
also substantially increased the rate of false positives (Berg WA, 2008). Automated 
whole-breast ultrasound  (AWBU) was judged to be beneficial if added to MG. The 
authors concluded that the method might be an alternative to the more costly MRI in 
high-risk women but that further research was warranted (Kelly KM, 2010). In Japan, 
women in general have denser breasts and breast-cancer incidence is highest between 
the late forties and the early fifties. In an article from Japan the authors concluded that 
US was equivalent to MG in detecting breast cancer in women in their forties, and that 
MG and US are complementary (Tohno E, 2009). However, they also found a lack of 
evidence for US as a single screening method for reducing mortality in breast cancer. 
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1.3.3 Magnetic resonance imaging  
Numerous studies indicate that the sensitivity of magnetic resonance imaging  (MRI) is 
superior to that of other imaging methods such as MG and US  (Warner, 2004) (Kriege, 
2004) (Kuhl CK, 2005) (Leach MO, 2005) (Weinstein SP, 2009) (Kuhl C, 2010) 
especially in young women and in BRCA1-or BRCA2- mutation carriers  (Warner E, 
2004).  
 
1.3.4 Clinical breast examination  
Clinical breast examination (CBE) is a standard procedure in women at high familial 
risk of breast cancer and is performed in connection with the annual visit to the 
clinician. Though widely used, this breast examination has not proved to decrease 
breast-cancer mortality. 
In a study by Gui et a., 1500 women at standard risk and 1078 women at moderate/high 
risk of breast cancer were monitored with annual CBE and MG. A total of 31 cancers 
were detected, of which 26 were palpable. Fourteen of these palpable cancers were not 
seen on MG and the authors concluded that CBE was an important component of the 
monitoring women at increased risk of breast cancer (Gui GP, 2001). 
 
1.3.5  Breast self-examination   
Breast self-examination (BSE) is frequently recommended to women in general and is 
also advocated for those at high risk of the disease. In contrast, the U.S. Preventive 
Service Task Force recommendation statement (USPSTF, 2010) for breast cancer 
screening does not recommend clinicians teaching women how to perform BSE. In a 
“meta analysis”, including two population-based randomised studies in altogether 
400 000 women in Russia and Shanghai, the authors concluded that BSE is not an 
effective surveillance method and that it does not lower mortality from breast cancer. 
Further, according to the review, BSE is associated with substantially more women 
seeking medical advice for different symptoms, and having biopsies (Kösters JP, 2003).  
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1.4 MAMMOGRAPHIC DENSITY 
High breast density may confer a 
mammographic sensitivity of only 30-
40%, and it represents an independent 
risk factor for breast cancer 
(Mandelson MT, 2000) (Kolb TM, 
2002). This risk was first described in 
the mid-1970s by Wolfe (Wolfe JN, 
1976). In a study by Boyd et al. the 
relative risk in women with very high 
breast density compared to women 
with lucent breasts was 6.05  (Boyd 
NF, 1995) while Chiu et al. found a 
relative risk of 1.57  (1.18-1.67) in 
dense breasts compared to fatty 
breasts  (Chiu SY, 2010). In studies of 
homo- and heterozygote twins, breast 
density was found to follow hereditary   
traits (Boyd NF, 2002). However, the 
increased breast cancer risk demonstrated in carriers of BRCA1 or BRCA2 mutations 
seems not to depend on mammographic density  (Gierach GL, 2010) (Mitchell G, 
2006).  
 
1.5 ATTENDANCE AT HEALTH CARE SURVEILLANCE  
 
1.5.1 Risk factors for non-attendance at surveillance programmes  
Studies in Sweden and other western countries have revealed several factors as 
predictive of non-attendance at population mammography screening. Such factors 
include no offspring and/or living without a partner, low or extra-high education and 
low income (Katz SJ, 2000) (Lagerlund M, 2002) (Aarts MJ, 2011).  
In agreement with these observations, descriptive reports of socioeconomic factors 
among women attending oncogenetic counselling clinics show that they tend to be 
well-educated and of middle or upper income status  (Bastani R, 1999) (Watson M, 
2005). There is, however, no published data suggesting that family clustering of breast 
cancer of genetic origin is more prevalent in higher socioeconomic groups. Reports of 
Mammographically dens breast- DY 
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an association between high socioeconomic status and an elevated risk of breast cancer 
(with an RR 1.1 – 3.5) are believed to reflect extrinsic factors rather than genetic factors 
(Braaten T, 2004).  
  
1.5.2 Socio - economic factors and breast cancer  
According to numerous studies, non-attendance in mammography screening 
programmes is associated with unfavorable socio-economic status (SES) and moreover 
to advanced disease (Zackrisson S, 2004). In a recent study from Holland women of 
low SES were found to have a significantly higher tumour stage at diagnosis than 
women with high SES. This was equally found among non-attendees, women with 
screen-detected cancers and women diagnosed with interval cancers (Aarts MJ, 2011).  
Altogether, studies on the influence of socioeconomic factors on women with breast 
cancer have demonstrated lower rates of survival among women of low SES  
(Kaffashian F, 2003). Although Rutqvist and Bern  (Rutqvist LE, 2006) observed a 
higher rate of survival among Swedish women with high income, more skilled work 
and a high level of education, these differences reflected the distribution of clinical 
stage of disease when diagnosed rather than a direct effect of socioeconomic variables. 
In contrast, in a recent study from the United States the difference in survival according 
to SES, favouring women with the highest level of education and household income, 
could only be partly explained by screening attendance and early detection (Sprague 
BL, 2011). The authors of that study conducted in the US concluded that research will 
be needed to understand the additional factors contributing to the remaining difference 
between women with differing educational levels. 
 
1.6 PSYCHOLOGICAL FACTORS AND ONCOGENETIC COUNSELLING   
Numerous studies have explored psychological factors in women attending oncogenetic 
counselling. In general they report worse scores for anxiety, distress and depression in 
women with a family history of breast cancer than in women in the general population 
(Cull A, 1999) (Martin W D. L., 2005) (van Dooren S, 2004). In contrast, a Swedish 
study of women undergoing pre-symptomatic testing for mutations in BRCA 1 / 2, 
showed no differences in vitality, mental health, role emotional functioning, social 
functioning or general health as compared to women in the Swedish population  (Arver 
B, 2004). In addition, in a Norwegian study individuals with hereditary risk of cancer 
were in better physical shape than, and similar mental shape to, the general population 
(Carlsson AH, 2004).  A Danish study of 213 women concluded that genetic 
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counselling does not appear to have a negative effect on general anxiety, symptoms of 
depression or Health related quality of life (HRQL) , and that counselling can help ease 
cancer-specific distress among women with an family history of breast cancer 
(Mikkelsen EM, 2009). 
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2 AIMS 
 
PAPER 1 
to search for putative breast-cancer-associated syndromes in families with 
two or more cases of breast malignancies; 
 
 PAPER 2 
   to characterize women at an oncogenetic counselling clinic in terms of 
socioeconomic status (SES) and health-related quality of life (HRQL),  
to compare SES  data from the women at the counselling clinic with population-
based data for women in the same catchment area,  
to compare HRQL in the studied sample with a normative age-matched sample 
from the general population,  
to compare different objective risk groups with respect to SES and HRQL; 
 
PAPER 3 
 to describe the design and the procedure of a prospective screening study,  
 
to describe the study cohort regarding hereditary patterns  and socio-
demographics,  
 
to report results of the first mammography ,ultrasound and clinical breast 
examination and 
 
to elucidate the associations between breast density and familial breast 
cancer risk, BMI and other breast-cancer risk factors. 
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3 MATERIAL AND METHODS 
 
The work presented in this thesis comprised three different studies with different study 
populations and methods. Consequently, the material and methods used are presented 
separately. 
 
3.1  PAPER 1 
 
3.1.1 Material 
 
In 2000 the Swedish National Oncogenetic Group decided to include all families in 
Sweden that had up to that point ever been subject to oncogenetic counseling at any of 
the eight counseling clinics in Sweden.  Altogether 4000 families were identified. For 
the purpose of this paper we sorted out the families with identified mutations in the 
BRCA 1 or BRCA 2 or in any of the genes that causes  increased risk of tumours of the 
colon as well as all families with breast or colon-only malignancies. At that stage 1648 
families remained. Approximately 50% of them originated from any of the three 
counseling clinics in Stockholm and, with descending contribution, clinics in Lund, 
Umeå, Gothenburg, Uppsala and Linköping contributed to the remaining 50 percent. 
Excluded families at this point were families with no case of breast cancer or families 
with only one case of the disease. Thus, the remaining 803 families represents the 
cohort of families in this paper.  
 
3.1.1.1 Study families 
 
Diagnoses from both maternal and paternal branches were included. Every case of 
cancer in first- and second-degree relatives, and in first cousins, was recorded. More 
than one study family could originate from one pedigree, depending on which pedigree 
branch was chosen. In this way, one case of cancer could be included in two, or 
sometimes three, study families; but no case of malignancy was ever counted more than 
once as an observed case of that particular type of tumour.  
Altogether, the 803 study families originated from 750 pedigrees. Most of the 
diagnoses were histologically verified from medical records or the Swedish Cancer 
Register. A few of the cases originated from the beginning of the twentieth century, 
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before the Cancer Register was established. These cases were mostly verified by 
checking the Swedish Cause of Death Register. 
 
3.1.1.2 Reference Population  
In addition to serving as a means of verifying diagnoses, the Swedish Cancer Register 
was used as a reference population in this study. In 1958, Sweden had 7.5 million 
inhabitants of whom 19 324 were reported to the Cancer Registry. In 1999 the 
corresponding figures were 8.8 million and 45 180.  
 
3.1.2 Method 
 
The proportion of different cancers other than breast cancer in the study families was 
computed and 95% confidence intervals (CI) were calculated. If the 95% CI did not 
cover the proportion from 1958 (or 1999) a significant difference from that year could 
be demonstrated. The population data were obtained from official Swedish statistics for 
two separate years and comparisons were made using statistics from the first and last 
years for which Swedish cancer statistics were available. Only malignancies with a 
significant difference in proportion compared with the general population in 1958 and 
1999 were considered over-represented. 
To permit comparison of the frequency of non-breast-cancers in our study families with 
data from Statistics Sweden, we corrected for the fact that 87% of the cancers reported 
in 1958 and 86% in 1999 were non-breast-cancers. 
 
 
3.2  PAPER 2 
 
3.2.1 Material 
 
3.2.1.1 Study population 
 
A consecutive series of 373 women attending genetic counselling at the oncogenetic 
outpatient clinic at Södersjukhuset, Stockholm, Sweden between 1 April 1998 and 1 
June 2004 were eligible for inclusion. A total of 306 women (82.5%) participated in the 
study. The criteria for attending the clinic and thus for eligibility for study, were wide, 
including at least one relative with breast, ovarian or breast/ovarian cancer. The vast 
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majority (82.3%) of the women had in their family history at least two close relatives 
with breast cancer.  
Women previously treated for breast and/or ovarian cancer or other malignancies were 
not eligible. As we chose to include in a consecutive manner following the woman’s 
first visit to the clinic, some women made only one visit, while others had attended 
several times when the questionnaires (see below) were sent.   
 
3.2.1.2 Reference population  
 
Socioeconomic status 
An age-matched reference population aged 25 to 74 years comprising all women living 
in the same catchment area at the time of the questionnaires (2004) was used  
(n= 277 783). 
 
Health related quality of life 
The reference population for health-related quality of life consisted of a normative age-
matched sample of Swedish women from the general population. The Short Form -36 
Health Survey (SF-36) was used. 
  
3.2.2 Method 
A questionnaire and an information letter explaining the purpose and the procedure of 
the study were sent to all 373 women by 1 June 2004. By answering and returning the 
questionnaire, the woman accepted to participate.   
 
3.2.2.1 Questionnaires and Reference sample 
 
Socioeconomic status  
The questionnaire addressing socioeconomic characteristics was developed for a study 
obtaining HRQL reference values in a large sample of the Swedish population. The 
questionnaire included three separate indicators of socioeconomic status (SES). 
Comparisons between data from study subjects and the population were explored using, 
for the reference population, figures from official statistics from three population-based 
registers. Each register cover close to100% of the reference population. 
• Marital status comprised four alternatives; “married or cohabiting”, 
“divorced/separated”, “widowed”, “single”.  
   21 
o Reference data on marital status was obtained through the Register of 
Total Population 2004. This is updated continuously and provides data 
on all individuals in Sweden. 
• Education consisted of three categories; elementary school (=9 years), 
elementary school + 2-3 years of upper-secondary, elementary school + 4-or 
more years of upper-secondary.  
o For reference values on education, the National Register of Education 
2004 was used. This register covers all individuals living in Sweden 
aged 16-74 and is updated every year with new data on the highest 
attained level of education. 
• Annual household income was classified in Swedish crowns (SEK) and 
upgraded compared to the original questionnaire as income brackets <300 000, 
300 001-500 000, >500 000 (300 000 - 500 000 SEK = 32 500 -54 200 Euro or 
44 000-73 300 USD 15.05.2007). 
o Economic situation for the reference population was obtained from the 
Register of Total Household Income 2004 which covers all sources of 
income subject to taxation, and therefore includes social benefits. 
Health-related quality of life 
The Short Form-36 Health Survey (SF-36), was used for assessing of HRQL. It consists 
of 36 items constituting eight subscales:  
-physical functioning (PF), role limitations as a result of physical problems (RP), 
general health perception (GH), pain (BP), role limitations as a result of emotional 
problems (RE), social functioning (SF), vitality (VT) and emotional well-being (MH).  
Higher score signifies better health. For each of the eight scales, the scores are summed 
and transformed to a scale of 0–100.  The Swedish version has shown good 
psychometric properties, and normative data for Swedish women are available.  
 
3.2.2.2 Statistics 
 
Descriptive statistics were generated for the study population regarding age at first visit 
and characteristics of family and family history. SES data from the study population 
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and from the reference population were compared using a one-sample test of proportion 
or a one-sample t test. 
Chi-square tests of independence were used for comparing categorical data between the 
three defined risk groups in the study population. For continuous data, the F test in 
linear regression models was used. In these regression models risk groups were 
represented by two dummy variables. Mean scores and 95% confidence intervals were 
calculated for each of the eight SF-36 subscales for the study population. Expected 
mean scores were calculated using age-specific mean-scale scores from normative 
Swedish data and the age distribution in the study population. One-sample t tests were 
used to compare observed and expected mean scores. 
 
3.3 PAPER 3 
 
3.3.1 Material  
 
Study participants were consecutively recruited between January 2002 and June 2006 
from the Familial Cancer Centre, Oncology Department, Karolinska University 
Hospital. This is located at three sites in Stockholm: Danderyd Hospital (site 1), 
Karolinska University Hospital (site 2) and Södersjukhuset (site 3).  All the women 
approached had had oncogenetic counselling and fitted into one of the four inclusion 
groups. A minor proportion of cancer diagnoses in the study subjects’ families were not 
verified due to insufficient data or foreign ancestry. Mutation screening of the BRCA1/2 
genes was offered to families according to Swedish National Oncogenetic Group 
guidelines.  A total of 659 women were approached for the study, 632 (94%) consented 
to participate. 
 
3.3.1.1 Inclusion criteria – four groups 
 
Suitable for inclusion were healthy women 25-60 years of age with a >17 % lifetime 
risk of breast cancer. Eligible women had either 
1. >17 % lifetime risk of breast cancer according to Claus tables, or 
2. a family history indicating an autosomal-dominant disease, with one or more 
first- or second-degree relatives with breast and/or ovarian cancer, or 
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3. a personal history of breast or ovarian cancer without signs of recurrence, with 
one or more first- or second-degree relatives with breast and/or ovarian cancer, 
or 
4.  mutation in BRCA1, BRCA2, PTEN or TP53 with or without a personal history 
of breast or ovarian cancer. 
Women with no known mutation in the family could be included from 10 years before 
the youngest family member was affected with the disease, while mutation carriers 
were eligible from 25 years of age. A normal mammogram one year before the first 
screening round was mandatory.  
 
3.3.2 Methods 
 
Study 3, which is still in progress, is a prospective, blinded, intraindividual, 
comparative surveillance cohort study.  The surveillance includes six annual screening 
rounds for MG, US, MRI, CBE and BSE.  The last screening round will be completed 
in June 2011. 
The paper reporting Study 3 is a first report. It includes a description of the main study 
design and the procedure, the study cohort regarding hereditary pattern and 
sociodemographics. Results of the first MG, US, and CBE are described. Associations 
between breast density, BMI and other breast-cancer risk factors are elucidated. 
 
3.3.2.1 Procedure 
Fig 3. Procedure – Flowchart for a woman included at site 2  
 
Blinding procedure 
No communication on findings between the radiologist and the study subject was 
permitted. The results from the three imaging modalities were sent in closed envelopes 
to the clinicians. No communication, regardless of finding, between the radiologists 
 
further investigation because 
one or more of the three  
exams  were suspicious 
CBE at site 2                             
summing up the results            
collection of questionnaire   
all exams are unsuspicious 
– no further  action until  
next year’s round
no more 
than 4 
weeks a 
part and in 
a random 
way of 
priority  
<8 weeks  later 
US done at site 1  
and 
MG done at site 2 
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and/or the clinicians involved in the study, was allowed before the annual CBE. The 
clinician was not permitted to open the envelope until the CBE was performed and 
documented. Subsequently all imaging results were disclosed and presented to the 
study subject. No more action was taken until the next screening round if all exams 
were normal.  
 
 
3.3.2.2 Imaging modalities 
 
Mammography  
All mammograms were double-read by two of five breast radiologists with at least 
twenty years experience. Mammography was performed with two views per breast 
(medi-oblique and craniocaudal) using analogue technique at both sites.  
 
Breast ultrasound  
All the US breast radiologists had more than fifteen years experience of clinical breast 
US examination. Both breasts including the axillas, were systematically examined by 
one of three breast radiologists.  
 
Magnetic resonance imaging 
No study subjects underwent MRI during the first screening round. 
 
Clinical breast examination 
The breasts and regional lymphatic areas were examined physically with the study 
subject sitting as well as lying down. All CBEs were performed by one of three 
oncologists, who all had more than five years experience of breast cancer diagnostics. 
 
Breast self examination 
All the women had been instructed to do monthly BSEs and were encouraged to 
contact the clinician if they noted any abnormality in the breasts.  
 
3.3.2.3 Breast assessment 
 
• Findings: The  MG, US and/or CBE findings were scored on a five-point scale; 
1= normal, 2= benign, 3= possibly malignant, 4= probably malignant and 5= 
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malignant. This is a modified version of a classification of mammographic 
findings described by Azavedo et al. and frequently used in Sweden (Azavedo, 
1989) 
• Density Mammographic density was estimated according to Wolfe’s division of 
breast density into four groups of increasing density: N1, P1, P2 and DY.  
• Easy or difficult to interpret To explore aspects of difficulty in interpreting the 
results of the imaging modalities, a dichotomized, subjective assessment was 
introduced. The breast radiologists categorized all images as easy or difficult to 
interpret.  
 
In case of abnormalities 
If there was an abnormality, code three or more on any examination modality, the study 
subject was mandatorily referred for further work-up to the radiologist who had 
detected the lesion. From this point on, all data from the examinations were made 
available to all the physicians involved in the work-up.                                                                             
Palpable lesions coded 3 or more were referred to a cytologist for fine-needle biopsy. 
(Referring for cytology was optional for codes below 3). If the diagnosis was still 
indeterminate after further work-up including additional views, spot compression views 
and core biopsy, an excision biopsy was performed.  
In pregnant or lactating women, only US imaging was used. CBE was done in all 
women.  
 
3.3.2.4 Lifestyle assessment 
A questionnaire was developed and captured demographic characteristics, medical 
history including history of gynaecological and/or breast surgery, reproduction history, 
external hormonal treatment, menopausal status, height and weight (body mass index), 
cup size, habits of self-examination and life style factors such as smoking, alcohol 
habits and physical activity.   The questionnaire was self-administered and collected in 
connection with the visit to the clinician, a procedure that will be repeated every six 
study rounds 
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3.3.2.5 Further risk assessment 
Since 2009 the Breast and Ovarian Analysis of Disease Incidence and Carrier 
Estimation Algorithm [BOADICEA] risk estimation model has replaced the Claus 
tables in the clinical setting. To compare old and new risk estimations, the lifetime risk 
(20-80 years of age) for each woman according to BOADICEA (21) was estimated 
retrospectively. 
 
3.3.2.6 Statistical analyses  
All data analyses were performed with the SPSS for Windows program, version 16.0. 
The main functions used for analysing the data were frequency tables, t tests , analyses 
of variance (ANOVA) and chi-square test for trend. Breast density as a dichotomous 
outcome, high versus low (N1 and P1 = low and P2 and DY = high), was analysed 
using binary logistic regression models. The factors used in the  analyses were children 
yes/no, risk group, premenopausal status yes/no, BMI at inclusion < 25 versus > 25, 
and mean age as a continuous variable. Forward stepwise binary logistic analyses were 
performed controlling for BMI and age. Approximately 5% of the values were missing 
from the variables used in the analyses. 
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4 RESULTS AND DISCUSSION 
 
4.1 PAPER 1 
Breast cancer in connection with other malignancies represents several known breast 
cancer syndromes such as breast and ovarian cancer syndromes in families carrying 
mutations in either suppressor gene BRCA1 or BRCA2, or the hereditary pattern seen 
in families harbouring mutations in p53 or PTEN. However, it is not known whether 
non-breast cancer malignancies apart from these syndromes in breast cancer families 
confer a risk on family members.  
 
In the 803 study families we found:  
Breast cancer   2203 cases   =2.7 cases per 
family 
35 different non-breast-cancer diagnoses 1 706 cases  =2.12 cases per 
family.  
 
Tumours in colon, ovary, endometrium, pancreas and liver, and leukaemia, were 
represented in an observed proportion with a 95% CI that did not cover the calculated 
proportion from official statistics in 1958 and 1999. Proportions of all non-
breast/ovarian tumours were also calculated and the same five malignancies (ovarian 
tumours not included), together with malignant tumours in connective tissue and 
larynx, had an observed proportion with a 95% CI that did not cover the proportions in 
the general population in 1958 and 1999. All the over-represented types of cancer, 
except for tumours in the larynx, were also present among the multiple-case families.  
 
 
Some malignancies were present in a smaller proportion of the study families than in 
the reference population: 
-   all cancers of the urinary tract, except for tumours of the kidney,  
-   all malignancies of the lymphoproliferative system, such as lymphomas and 
myelomas together. 
Syndromes described earlier could, at least in part, explain the higher frequency of 
ovary and pancreatic tumours in the study families, and leukemia. The excess of ovary 
and colon cancer could partly be a result of confounding by indication and the excess of 
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malignancies in the liver could depend on secondary tumours in the study families. 
However, we conclude that endometrial carcinoma has not been described earlier in 
that context, suggesting that endometrial carcinoma and breast cancer could constitute a 
new breast cancer syndrome. 
    
In 2000 Mutter et al stated that decreased function of the PTEN suppressor gene is a 
marker of precancerous lesions in the uterus and a major gene involved in the 
pathogenesis of endometroid endometrial adenocarcinoma (Mutter GL, 2000). 
Accordingly, in the list of operational criteria for the diagnosis of the Cowden 
Syndrome (CS) established by the International Cowden Consortium, endometrial 
cancer was added to the major criteria for the syndrome (Eng, 2000). Eng concluded  
that endometrial carcinoma might be a major CS cancer, and the presence of tumours of 
endometrial origin might be important in finding mutations in the PTEN gene in 
counselled families. The risk of endometrial cancer in PTEN mutation carriers is 
estimated to be 5 -10%.  In our data set of 124 families with both breast and 
endometrial cancer, five also presented one case each of thyroid cancer. However, no 
further analysis has been undertaken to clarify whether these families could constitute a 
subgroup of families with Cowden Syndrome in our cohort. 
On the other hand, a histological study by Liang et al found certain tumours of the 
endometrium, endometrial serous carcinoma, to be more prevalent in women 
previously treated for breast cancer than was endometroid carcinoma of the uterus, 
especially in women under 50 years. They also cited our suggestion that endometrial 
cancer together with breast cancer could constitute a new breast- cancer syndrome 
possibly in accordance with their findings. Further investigation is warranted to 
categorize phenotypes of endometrial tumours in this subgroup of malignancies in our 
study sample. 
   
 
 
 
4.2 PAPER 2 
4.2.1 Results and Discussion socio-economic status 
The characteristics of the study groups with respect to age at the time of the first visit to 
the clinic, description of family, family history and documented objective risk did not 
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differ significantly  in the majority of cases from the corresponding characteristics of 
the eligible women who declined participation (n=65, 17.5 %). At the same time, the  
mean values of all three socioeconomic indicators for the study group and other women 
in the same geographical area did differ significantly.  
Table 2. Comparison of women 25-74 years seeking oncogenetic counselling and women from the 
general population (25-74 years) in the same catchment area. 
 
Variable  Study group (n=306)  General population  P‐valuea. 
       
Age (95%CIb)  44.0 (42.7 to 45.2)  46.1  0.001 
       
Marital status:       
Married  74.2%  43.8%   
Divorced  10.5%  17.7%   
Widowed  1.6%   3.9%   
Single  13.7%  34.6%  <0.001 
       
Education level:       
Elementary school  7‐9 years  9.5%   17.3%   
Elementary school + 2‐3 years  33.9%  43.1%   
Elementary school +>4 years  56.7%  39.6%  <0.001 
       
Household income:       
<300 000 SKr  27.2%  57.9%   
300 001‐500 000 SKr  36.2%  29.3%   
>500 000 SKr  36.6%  12.9%  <0.001 
         
aFrom Chi‐square goodness of fit test or one‐sample t‐test. 
bConfidence interval. 
Information regarding the general population (n=277 783) refers to the year 2004. 
 
The same differences between our subjects and the reference population were observed 
when the study group was divided into sub-groups on the basis of risk of developing 
breast cancer: low (<21%), intermediate (21-39), high (40-80%), youngest age at which 
breast cancer was diagnosed in another member of the family (<40, 40-49, >49 years) 
or the death of an immediate relative from this disease.  
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Table 3. Family and socio-economic characteristics by riskgroup  
In a population-based study conducted in the Geneva canton of Switzerland covering 
all incidents of breast cancer diagnosed during 1990 -1999, women with and without a 
family history of breast cancer were compared regarding detection of breast cancer by 
surveillance, stage at diagnosis, likelihood of adequate treatment and survival 
(Verkooijen HM, 2009). The authors demonstrated, somewhat in contrast to our 
findings, that the presence of a positive FH eliminates differences in access to screening 
and optimal treatment. However, differences in stage at diagnosis and subsequent 
mortality were still unfavorable in women of low socioeconomic status (SES) 
regardless of a present FH or not. However, selection to that study was population-
based and did not reflect women at a counselling clinic.  
On the other hand, one could speculate that  women in that study had a lower barrier to 
get a mammography than ‘our’ women who first had to have counselling which most 
often during the pedigree-procedure, includes contact with more or less close relatives 
– which can be seen as an obstacle. In addition, to reach a counsellor implies making 
contact with the health and welfare system on one’s own initiative – which in itself can 
be an obstacle. 
  Risk group (%)   
Characteristic  Low 
(n=117) 
Intermediate 
(n=56) 
High 
(n=124) 
P‐valueb 
         
Age, mean  (SD)  42.2 (9.0)  45.5 (10.6)  45.3 
(11.3) 
0.033c 
         
Youngest age at diagnosis of breast 
cancer in the familya, mean  (SD) 
46.1 (10.6)  43.4 (6.6)  44.3 (7.6)  0.11c 
         
Close relative died of breast cancer  40 (34)  28 (50)  49 (40)  0.14 
         
Cohabitant  86 (74)  41 (73)  93 (75)  0.95 
         
Higher education  70 (60)  32 (57)  67 (54)  0.66 
         
aSeven women are excluded from analysis when information regarding age at diagnosis of breast cancer are 
missing. 
bP‐value from chi‐square test of independence. 
cP‐value from F‐test in a linear regression model. Risk group is represented by two dummy variables in the 
model. 
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4.2.2 Results and Discussion Health related quality of life 
The study sample scored lower than expected on five of the eight subscales, whereas 
three  subscales relating to physical health showed mean scores close to expected. As 
age differences were found between the risk groups, this variable was accounted for in 
the analysis of HRQL (SF-36). No statistical differences in HRQL were found between 
the risk groups.  
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Fig. 4 Difference between observed and expected scores 
 
When the study group was divided according to highest level of education, the same 
differences between all three sub-groups and the reference values were seen (data not 
shown). This was also the case when the study group was subdivided on the basis of 
objective estimated risk of developing breast cancer (data not shown). In contrast, there 
were no significant differences between the sub-groups. 
 
Study subjects’ SF-36 scores were affected neither by highest educational level nor 
degree of objective risk of breast cancer. However, we cannot conclude anything from 
our results about why these women sought counselling. Hence, we do not know 
whether these women were in general worried and anxious and would have had the 
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same SF-36 scores irrespective of an increased risk of breast cancer. Or whether, before 
knowing about a possible increased risk, they would have had SF-36 scores in parity 
with normative data. Nor do we know if their mental health will change over time. 
 
4.3 PAPER 3 
 
A total of 659 women were approached for the study and 632 consented to participate. 
 
Baseline data 
Baseline data including social status, educational level, health-related factors and 
hormonal-related factors are presented.  
Example: 
Married or living with partners  471 (77%)  
Had children   492 (78 %)  
Had an academic degree   398 (63%)  
 
Ages ranged from 25 to 60 years, with a mean age of 44.1. The mean age was 
statistically significantly higher in Risk Group 3 (see below) than in the other risk 
groups. No major differences regarding baseline data were found between the four risk 
groups.  
 
Risk assessment and defining risk groups 
The pedigrees were defined regarding hereditary pattern and divided into 16 different 
subgroups. Subsequently these subgroups were classified according to the lifetime risk 
of breast cancer.          
 
Four risk groups were defined:  
1. Moderate risk of breast cancer;    173 women 
2. High risk of breast cancer;    387 women 
3. Heredity and own history of breast- or ovarian cancer 26 women 
4. Very high risk, mutation carriers +/- breast- or ovarian cancer 46 women 
 
In the retrospective analyses using the BOADICEA risk estimation model and a cut-off 
value of >17 % lifetime risk of breast cancer, 217 (34 %) of the women would not have 
been eligible for surveillance in this study. 
 
 
Encoding mammography, breast ultrasound, clinical examination and further 
work-up 
All the breast MG (n=612), US (n=624) and CBE (n=627) were blinded to the people 
conducting the other two. No statistically significant differences were found regarding 
the coding for the different breast examination methods between the risk groups or age 
groups.   
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Mammographic evaluation 
No lesions suspicious for malignancy (codes 4 and 5) were identified by the MG breast 
radiologists. In 18 cases (17 with code 3 and one with code 2) supplementary 
mammographic images were recommended and seven of these women needed further 
investigation with stereotactic biopsy.  
 
                                                                                                                                                                                     
Subjective experience of reading the mammographic images   
 
Table 4 Mammography - Easy or difficult to interpret in relation to density pattern 
                                                                  
Mammography ‐ Easy or difficult to interpret in relation to density pattern 
  DY + P2            (%)  P1 + N1           (%)  Total number      (%) 
Difficult  165 / 411         (40.1)  22 / 199        (11.1)  187 / 610             (30.6) 
Easy  246 / 411         (59.8)  177 / 199      (88.9)  423 / 610             (69.3) 
Total number  411  199  610 
 
 
Ultrasound evaluation 
The US breast radiologists identified two women with a code-4 lesion and one with a 
malignant  lesion, code 5. In total 75 women were recommended additional work-up 
with fine-needle biopsy or ultrasound-guided core biopsy.   
                                                     
Subjective experience of reading the ultra sound images 
 
Table 5 Ultra sound - Easy or difficult to interpret in relation to density pattern 
 
 
 
 
 
 
 
Clinical breast examination 
The clinicians referred 89 women for further work-up with cytology. These clinical 
findings were coded as follows: code 1– 4 cases, code 2 – 48 cases, code 3 – 36 cases, 
code 4 – 1 case, code 5 – 0 case.  There were 87 benign findings among CBE-referred 
cytology, one atypia but no malignancy.   
 
 
Ultra sound ‐ Easy or difficult to interpret in relation  to    density pattern 
  DY + P2                (%)  P1 + N1               (%)  Total number     (%) 
Difficult    93 / 411           (22.6)     25 / 197           (12.7)  118 / 608            (19.4) 
Easy  318 / 411           (77.4)  172 / 197            (87.3)  490 / 608            (80.6) 
Total   411  197  608 
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Breast self exam  
 
 
Fig 5 BSE in different age groups     
 
Fig 6 BSE in different risk groups 
 
 Breast density and fine-needle referrals  
 
Table 6. Breast density and fine-needle referrals  Table 7. Breast density and fine-
needle referrals MG                needle referrals US 
 
N=fine needle cytology referred from MG   
Total number= 7 
density  N/ total number density category   
DY        1/60   (1.7)   
P2                        4 /355  (1.1)   
P1       2 /169  ( 1.2)   
N1       0 /30   ( 0.0)   
N=fine needle cytology referred from US    
Total number= 77 
density N/ total number density category   
DY        8 /60        (13.3)   
P2                   48 /355     (13.5)   
P1      19 /169     ( 11.2)   
N1         2/30          ( 6.6)   
Table 8. Breast density and fine-needle CBE 
referrals 
 
N=fine needle cytology referred from CBE   
 Total number= 87 
density  N/ total number density category   
DY      8/60       (13.3)   
P2                  59/355      (16.6)   
P1    18/169     ( 10.7)   
N1     2/30        ( 6.6)   
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Breast density in different risk groups and age groups 
 
To identify any predictors for high density, multivariate analyses were used. The two 
density groups N1 and P1 were merged and defined as low density (n=199), while P2 
and DY were merged and defined as high density (n=413).  
BMI < 25 and low age were statistically significant predictors of high breast density in 
both the univariate and the multivariate analyses. Non-significant competing factors 
were children y/n, risk group, and premenopausal vs. postmenopausal status. 
 
Many studies have reported that there seems to be no association between BRCA1and 
BRCA2 carrier status and breast density (Gierach GL 2010) (Mitchell G 2006). 
Likewise, many studies have reported density to be associated with heredity for breast 
cancer (Martin LJ 2010)(Boyd NF 2002). As far as we know, ours is the first study to 
interpret the association between density and increasing risk of familial breast cancer. 
To evaluate density we chose Wolfe’s well-established pattern-based method (Wolfe, 
1976) which may be less specific than quantitative-based scales for classifying highly 
dense breast. However, in a recent study by Garrido-Estepa et al both methods were 
considered to have high reproducibility (Garrido-Estepa M, 2010).  
To elucidate the association between difficulty in reading breast images and breast 
density, a second subjective scale was introduced: all the breast radiologists judged 
whether the breasts were easy or difficult to read. It is less known whether 
mammographically dense parenchyma also affects the assessment of ultrasound and / 
or CBE thereby occasioning a need for further work-up. For breast evaluated as DY or 
P2, there were numerically higher percentages of referrals for fine-needle biopsies from 
all three examination methods.   
 
Mammographic breast results evaluated as DY were much more frequently interpreted 
as difficult to read on MG than on US, 75% vs. 24%. However, it is too early to 
conclude whether there is any diagnostic relevance in this subjective method.  
 
The study included at least three visits per screening round for the participating women. 
Despite this, only 6 % of the women we approached declined to participate and also, 
only a few women dropped out because the study was too time-consuming.  
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Concerning socioeconomic status a  majority of the women were well-educated and 
married or cohabiting, which agrees well with many previous descriptive reports of 
women who visit oncogenetic counselling clinics  (Bastani R 1999) (Watson M 2005) 
and with previous findings from the Stockholm area (paper 3)  (Von Wachenfeldt  A, 
2009). Paper 3 included patients from two sites, northern and south Stockholm.         
We are aware that some of the present subjects (from site 3) in this study also 
participated in paper 2.  On the other hand, no statistically significant differences in 
baseline data between the study sites were found, although income and levels of 
education differ between these catchment areas in the Stockholm region 
(www.socialstyrelsen.se 2011). We believe that the high participation in the study 
permits generalization of the results to other women seeking oncogenetic counselling.  
 
It is difficult and challenging to categorize women into different risk groups regarding 
risk of breast cancer due to hereditary factors in families with no identified mutation. 
Claus tables are widely used; however, they include no more than two close relatives 
for estimating lifetime risk of breast cancer. Many different types of risk estimation and 
risk categorization have been used in oncogenetic studies (Berg WA, 2008) (Kriege M, 
2004)  (Weinstein SP, 2009) (Schmutzler, 2006). Our estimation was based on the 
pedigree pattern, as this risk has been estimated by others (Schmutzler RK, 2006) (Kuhl 
CK, 2005) while other authors base their estimation on percentage risk from the Claus 
tables / or the Gail model (Kriege M, 2004) (Weinstein SP, 2009).  
 
A third of our study population was classified as being at moderate risk and 2/3 as 
being at high risk, which is similar to the risk groups in a study by Kriege et al. (5), 
who used modified Claus tables (20) for risk estimation.  Thus, our risk categorization 
and Claus tables resulted in approximately the same distribution between risk groups 
and are hence presumably comparable.  
The new BOADICEA risk assessment model has recently been introduced in Swedish 
clinics. Notably, using this model, 34% of ‘our’ women would not have been eligible if 
a threshold of 17% lifetime risk had been used. Evaluation of whether BOADICEA is a 
more appropriate risk assessment method to predict breast cancer in this cohort will be 
a topic for another report.  
 
The referrals to fine- needle biopsy from US were 77/624 (12.3%) and from CBE 
87/627 (13.9). We believe that these considerably high numbers reflect, at least in part, 
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the limited experience of using these two methods as single screening methods. Berg et 
al concluded that adding US to MG in a single screening round added sensitivity in 
terms of breast malignancies being diagnosed, but also substantially increased the 
number of false positives. The next five rounds of this large, prospective, screening 
study will show whether this will change over time as the specialists using the two 
methods get more experienced. The lower number of referrals for cytology from the 
MG radiologists may be the consequence of their long experience of using MG as a 
single screening method. Recall rate for MG in this study was 18/ 612 (2,9%) which 
tallies with rates from the population screening program in Sweden (3%) (SBU2011).  
 
We felt that women who have been alerted to their increased risk of breast cancer could 
not, for ethical reasons, be denied surveillance. Hence, no reference group was used, 
which is a limitation of the study. Further, digital technique is more accurate for 
reading dense breast and breast in women < 50 years of age (Pisano ED, 2005) but at 
the time of the first screening round, analogue mammographic technique was used – 
another weakness. During subsequent screening rounds digital technique was being 
introduced gradually at both MG sites (sites 2 and 3). 
 
In conclusion, high breast density in a population of women with family history of 
breast and/or ovarian cancer is associated with low BMI and young age but not with 
increasing familial risk of the disease.  The number of detected cancers did not 
significantly differ from the expected numbers. However, it is too early to draw any 
conclusion about the sensitivity of the three different test modalities. Ultrasound and 
clinical breast examination caused substantially more work-up than MG. 
In addition, the size of the study population and the thorough risk categorization, in 
combination with the blinded procedure, will enable us to explore strengths and 
limitations of the breast examination modalities investigated.    
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5 CONCLUSIONS AND CLINICAL IMPLICATIONS 
 
PAPER 1 
We suggest that endometrial carcinoma and breast cancer could constitute a new breast 
cancer syndrome. 
Further investigation is warranted to categorize phenotypes of both breast and 
endometrial tumours in this subgroup.  
 
PAPER 2 
SES 
Women attending public oncogenetic counselling because of breast cancer in one or 
several close relatives are more often living with spouses/partners, have higher 
education level and higher household income than age-matched women from the same 
catchment area. 
 
This indicates a higher awareness of, and/or availability to, oncogenetic counselling 
among women of high socioeconomic status (SES) than among those with low SES.  
Efforts should now be made to facilitate for women of lower SES and with increased 
risk of breast cancer to be considered for counselling and, if indicated, subsequent 
intensive breast cancer screening. 
  
HRQL       
Women attending oncogenetic counselling because of breast cancer in one or several 
close relatives exhibit lower levels of HRQL for subscales related to mental health and 
for general health but have levels equal to normative data for all other items that 
evaluate physical health.  
                                             
If a woman experiences a moderate, high or very high risk of breast cancer, this does 
not affect how she answers questions reflecting her mental and general health. 
These findings require further study to elucidate how information about increased 
risk of breast cancer affects women over time.  
 
PAPER 3 
High breast density in a population of women with family history of breast and/or 
ovarian cancer is associated with low BMI and young age. 
 
High density is not associated with increasing risk of breast cancer.  
 
The number of detected cancers did not significantly differ from the expected numbers. 
However, it is too early to draw any conclusion about the sensitivity of the three 
different test modalities.  
The next five screening rounds will, thanks to the thorough risk categorization in 
combination with the blinded procedure and the size of the study population, enable us 
to explore strengths and limitations of the breast examination modalities investigated in 
women at familial risk of breast cancer.  
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